S
Setsuko K. Chambers
Researcher at University of Arizona
Publications - 158
Citations - 7181
Setsuko K. Chambers is an academic researcher from University of Arizona. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 45, co-authored 153 publications receiving 6016 citations. Previous affiliations of Setsuko K. Chambers include Yale University & University of Rochester.
Papers
More filters
Journal ArticleDOI
The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients
Barry M. Kacinski,Setsuko K. Chambers,E. Richard Stanley,Darryl Carter,Paul C. Tseng,Kimberly A. Scata,David H.Y. Chang,Mary H. Pirro,Josephine T. Nguyen,Aurelio Ariza,Larry R. Rohrschneider,Victoria M. Rothwell +11 more
TL;DR: Autocrine and paracrine effects mediated by tumor or stromally produced CSf-1 and a tumor epithelial cell CSF-1 receptor may contribute to the biological behavior of endometrial neoplasms in vivo and in vitro.
Journal ArticleDOI
Ovarian germ cell malignancies: The Yale University experience
TL;DR: Conservative surgery to preserve reproductive function is appropriate for all patients with early stage ovarian germ cell malignancies and selected patients with advanced disease.
Journal ArticleDOI
Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival
Fredric V. Price,Setsuko K. Chambers,Joseph T. Chambers,Maria Luisa Carcangiu,Peter E. Schwartz,Ernest I. Kohorn,E. Richard Stanley,Barry M. Kacinski +7 more
TL;DR: In this paper, the concentration of colony-stimulating factor in ascites of ovarian carcinoma is determined to be a prognostic factor for survival in patients undergoing primary surgery for ovarian cancer.
Journal ArticleDOI
Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial.
Peter E. Schwartz,Joseph T. Chambers,E.I. Kohorn,Setsuko K. Chambers,Hervey Weitzman,I.M. Voynick,Neil J. MacLusky,Frederick Naftolin +7 more
TL;DR: It is suggested that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.
Journal ArticleDOI
Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152
TL;DR: The results provide the evidence for a mechanism by which miR-128 andMiR-152 down-regulate CSF-1, an important regulator of ovarian cancer.